Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint
Yves Agid(Sorbonne Université), Eduardo Tolosa(Biomedical Research Networking Center on Neurodegenerative Diseases), William C. Koller(Stanford University), Stanley Fahn(Columbia University Irving Medical Center), Christopher G. Goetz(Rush University Medical Center), Rita Raisman‐Vozari(Centre National de la Recherche Scientifique), Peter A. LeWitt, Patrick P. Michel(Centre National de la Recherche Scientifique), Fabrizio Stocchi(San Raffaele University of Rome), Dorothy Marsden, Justo De Yebenes, Werner Poewe(Innsbruck Medical University), Stewart A. Factor(Parkinson's and Movement Disorder Institute), Wolfgang H. Oertel(Philipps University of Marburg), Andrew J. Lees(Centre for Movement Disorders), Eric Ahlskog, Matthias Kurth, Oscar S. Gershanik(Instituto de Neurología Cognitiva), Alberto Albanese(Università Cattolica del Sacro Cuore), Y Mizuno(Juntendo University), Warren Olanow(Mount Sinai Medical Center), Donald B. Calne(University of British Columbia), N Quinn, J. A. Obeso(Sonora Institute of Technology), E. Melamed, Thomas N. Chase, A. H. Rajput, S. Przedzorski, Pierre Pollak(School of the Art Institute of Chicago), Anthony E. Lang(University of Toronto)
Cited by 88
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k